Cohance Lifesciences Limited has informed the Exchange regarding a press release dated July 28, 2025, titled "Press Release".
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences has appointed Mr. Yann D'Herve as the Chief Executive Officer of its Contract Development and Manufacturing Organization (CDMO) business, effective August 1, 2025. D'Herve most recently served as Senior Vice President and General Manager of Evonik's Healthcare division, where he oversaw 2,600 employees across nine manufacturing sites with full P&L responsibility. He brings extensive experience in manufacturing, strategic management, and commercial operations across pharmaceuticals, healthcare, and specialty chemicals. Cohance's CDMO platform covers small molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry, serving global pharmaceutical companies. Executive Chairman Vivek Sharma stated that D'Herve's global pharmaceutical services experience will help accelerate the growth of the CDMO platform.
This is a senior leadership change that could be viewed positively by investors, as the new CEO brings strong global CDMO and P&L experience from Evonik. The appointment may signal a focus on scaling the CDMO business, though the actual impact on stock price will depend on execution and future performance disclosures.